This is just Part of an Article a Son sent me tonight. Shag
I realize that the over-used expression..."cancer breakthrough"...is an instant turn-off to disillusioned biotech investors who have been fed over-hyped and exaggerated promises for decades.
But, I just don't know how else to summarize the technology that a little-known, start-up biotech company by the name of BioCurex (OTCBB: BOCX) has now patented/patent pending in over 20 countries.
Spend three minutes reading this report and you'll see for yourself that we're talking about a simple (they're the best kind) effective and affordable technology that is on its way to push early detection of cancer to the next level.
Cancer Testing
I'll tell you the clinical details in a moment.
But first, let me be clear: It's wonderful that a significant breakthrough has been made in the detection of cancer... BUT...this is about making money. Lots of it! By buying what I personally consider an over-looked, under-valued stock now, before Wall Street wakes up to its staggering profit potential.
The name of the company is BioCurex. Its scientific Advisory Board reads like a "who's who" of the cancer research field. The OTCBB symbol is BOCX. Their Website is www.biocurex.com. But I'm going to tell you here what the company attorneys are afraid to say in their official releases, namely that, in my opinion:
This stock is poised for lift off
My name is Eric Dany and I'm the editor of the highly-successful, advisory, the Stock Prospector. And let me tell you right off the bat... I'm always looking for undiscovered, under-valued, high potential stocks with explosive potential.
Stocks that have the potential to generate near-term gains of 200-500% and, because they are solid, well-managed, well-financed companies with some sort of unique and special industry advantage they ought to keep going turning in long-term gains of 1,000% and more.
I look for significant trends like out-of-control medical costs. And anything that's going to cut health care costs is a sure winner
Now I'm recommending a small, mostly-overlooked company with a revolutionary way to detect cancer, earlier, with less cost and more accuracy, that could set the cancer screening industry on its ear! Here's the short version of the BioCurex story and why you need to logon to your trading account now and buy this stock:
The opportunity: until now, even the best cancer detection tests (and very few are available) were only 40-60% accurate. These tests don't work very well and have too many false readings. They frequently miss early-stage cancers. As much as 20% of the time, they generate costly and alarming "false negative" results which means they miss finding the cancers. What's more, many of them are time-consuming, can cost over 1,000 dollars and they still aren't accurate!
The solution: Researchers at BioCurex have identified a unique molecular marker (it's called RECAF) that is present in cancer cells, but almost absent in healthy cells and they have developed a patented technology for detecting this marker using a simple, affordable blood-based procedure.
Here's why BioCurex is a buy:
* RECAF is the only marker common to all the major types of cancerous tumors.
* The BioCurex test for RECAF is extremely sensitive and 90% reliable in detecting even early-stage breast and lung cancers, for which there are no good cancer markers; and does the same remarkable detection for prostate cancer compared to a rate of just 40-60% for the currently most-used screens.
* The technology is already patented in the U.S. and is patented/patent pending in over 20 foreign countries.
* The total world-wide market for what BioCurex offers is so large it is not even possible to predict, since the test can be used for monitoring patients who want to detect any early recurrence of a cancer; for assisting the diagnosis of patients who have pain or swellings; and even for mass screening of the population over 40. I can easily imagine the day when everyone over the age of 40 has this test to find out if they have cancer OR NOT.
* A cheap and reliable technology that catches most cancers with high accuracy could save insurance companies and Medicare tens if not hundreds of millions of dollars every year in treatment costs
* The stock (OTCBB: BOCX) is trading at under a dollar a share. I believe it is way undervalued and poised for explosive growth!
The market is immense, the need for better detection urgent:
Cost of Cancer in the U.S.
Worldwide, there are 10,800,000 new cases of cancer reported each year. About 6,700,000 people die of cancer every year. Cancer is the leading cause of death after heart disease. For men, the odds of developing cancer are one in two. One in three women will develop cancer. 75 people die every hour from prostate cancer, breast cancer and lung cancers!
The annual cost of cancer care in the U.S. is estimated at more than $143 billion! While cancer treatments are improving survival rates, it's obvious that better early-detection could save millions of lives a year in the US alone. Early detection is critical to successful treatment, which is why so much is spent on cancer screening:
* In the US alone over $2 billion is spent each year on routine mammography that searches for breast cancer, yet in 25-40% of the cases in which a tumor is visible, the radiologist cannot tell if it's cancerous or benign. The BioCurex screening will cost far less, and according to results presented by the company in several cancer congresses, it would be more accurate and more convenient.
* We spend $900 million a year on Pap smear testing for cervical cancer (with only 50% sensitivity). BioCurex results on 25 cervical cancers show 92% sensitivity.
* The $500 million a year spent on prostate screening (with only a 40-60% accuracy)
* The $350 million a year on colorectal screening.
* And the millions of dollars spent on all the other cancers.!
A lot of other tests involve expensive time-consuming radiology or painful biopsies. All of them, more than $2 billion worth a year, could be replaced or at least coordinated with a simple, fast, low-cost and far more accurate blood test that simply screens for the tell-tale molecular marker, RECAF.
Here's why the acceptance of this RECAF technology is virtually certain:
Rather than over-load you with technical data, I'm going to use prostate cancer as a more detailed illustration of why BioCurex's RECAF technology represents a paradigm shift in cancer testing:
Right now, PSA is a test used for prostate cancer and is recommended for men over the age of 50. The sales approach 500 million dollars per year. BUT the main problem with conventional PSA testing for prostate cancer is that it can't accurately tell the difference between prostate cancer and benign prostate conditions.
Cancer Cells
According to a study presented at the Annual Meeting of the American Association of Clinical Chemistry, in a test of 100 known cancer patients and 30 patients with benign lesions, the standard PSA test showed a sensitivity of 48% with 60% specificity. This means that the test missed over half the cancers and that 40% of the patients were needlessly subjected to costly and uncomfortable biopsy of their prostate.
Using the company's RECAF test on the same cancer and benign samples, the sensitivity was 90% with a specificity of 84%!!!. When the cancer samples were compared with samples from normal individuals, both the sensitivity and the specificity of the RECAF test approached 100%.
News 
Market Data 
Discover 
